anifrolumab   Click here for help

GtoPdb Ligand ID: 8258

Synonyms: anifrolumab-fnia | MDX-1333 | MEDI-546 | Saphnelo®
Approved drug Immunopharmacology Ligand
anifrolumab is an approved drug (FDA (2021), EMA (2022))
Compound class: Antibody
Comment: Anifrolumab is a monoclonal antibody targeting IFNAR1 (the receptor for α, β and ω interferons), that was developed by the MedImmune subsidiary of AstraZeneca as a treatment for systemic lupus erythematosus (SLE).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. [3]. Sequence BLAST using the heavy and light chain variable regions of anifrolumab provides 100% matches to sequences that are claimed in patent US7662381 [3]. The sequence matches identify anifrolumab as clone 11E2 in the patent.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Batteux F, Palmer P, Daëron M, Weill B, Lebon P. (1999)
FCgammaRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus.
Eur Cytokine Netw, 10 (4): 509-14. [PMID:10586117]
2. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. (2001)
Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.
Science, 294 (5546): 1540-3. [PMID:11711679]
3. Cardarelli JM, Witte A, Srinivasan M. (2010)
Interferon alpha receptor I antibodies and their use.
Patent number: US7662381. Assignee: Medarex, Inc.. Priority date: 21/06/2004. Publication date: 16/02/2010.
4. Foulis AK, Farquharson MA, Meager A. (1987)
Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus.
Lancet, 2 (8573): 1423-7. [PMID:2891993]
5. Hooks JJ, Jordan GW, Cupps T, Moutsopoulos HM, Fauci AS, Notkins AL. (1982)
Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis.
Arthritis Rheum, 25 (4): 396-400. [PMID:6176247]
6. Luft T, Luetjens P, Hochrein H, Toy T, Masterman KA, Rizkalla M, Maliszewski C, Shortman K, Cebon J, Maraskovsky E. (2002)
IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells.
Int Immunol, 14 (4): 367-80. [PMID:11934873]
7. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, Cebon J. (1998)
Type I IFNs enhance the terminal differentiation of dendritic cells.
J Immunol, 161 (4): 1947-53. [PMID:9712065]
8. Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, Glaspy JA. (1998)
Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells.
J Leukoc Biol, 64 (3): 358-67. [PMID:9738663]
9. Radvanyi LG, Banerjee A, Weir M, Messner H. (1999)
Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells.
Scand J Immunol, 50 (5): 499-509. [PMID:10564553]
10. Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F. (2000)
Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.
J Exp Med, 191 (10): 1777-88. [PMID:10811870]
11. Ytterberg SR, Schnitzer TJ. (1982)
Serum interferon levels in patients with systemic lupus erythematosus.
Arthritis Rheum, 25 (4): 401-6. [PMID:6176248]